The Rising Concern of Rectal Cancer: Causes, Diagnosis and Treatment Options

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".

Deadline for manuscript submissions: 20 September 2024 | Viewed by 1562

Special Issue Editor


E-Mail Website
Guest Editor
General, Emergency and Trauma Surgery, Maurizio Bufalini Hospital, Cesena, Italy
Interests: laparoscopy; colo-rectal surgery; geriatric surgery; emergency surgery; oncology surgery

Special Issue Information

Dear Colleagues,

The management of rectal cancer represents a major challenge in our daily clinical practice. From pathogenesis to diagnosis to treatment, rectal cancer knowledge is progressively evolving year after year and is a cutting-edge topic in the recent literature. In this Special Issue of the “Journal of Clinical Medicine” we want to further investigate recent progress in this fascinating field from a wide range of perspectives. The diagnosis of rectal cancer is growing increasingly accurate and research aims to propose a patient-tailored treatment, especially in the field of chemotherapy and radiotherapy. Several oncological innovations are ongoing. Moreover, endoscopy plays a pivotal role in the diagnosis and in the treatment flow-chart of rectal cancer, especially in the emergency setting. Surgery remains one of the mainstays of rectal cancer treatment and one of the fields of major surgical research interest due to the applications of robotic and transanal minimally invasive techniques. A true challenge is the emergency presentation of rectal cancer due to the onset of bowel obstruction, as well as the peritoneal spread of the disease with the development of peritoneal carcinomatosis. In this Special Issue, we welcome authors to submit papers on the clinical advances of rectal cancer management in terms of both diagnosis and treatment.

Dr. Carlo Vallicelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rectal cancer
  • robotic surgery
  • transanal TME
  • colo-rectal carcinomatosis
  • chemotherapy
  • radiotherapy

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 601 KiB  
Review
Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer
by Francesco Giulio Sullo, Alessandro Passardi, Chiara Gallio, Chiara Molinari, Giorgia Marisi, Eleonora Pozzi, Leonardo Solaini and Alessandro Bittoni
J. Clin. Med. 2024, 13(9), 2562; https://doi.org/10.3390/jcm13092562 - 26 Apr 2024
Viewed by 515
Abstract
Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, distant tumor recurrence [...] Read more.
Rectal cancer presents a significant burden globally, often requiring multimodal therapy for locally advanced cases. Long-course chemoradiotherapy (LCRT) and short-course radiotherapy (SCRT) followed by surgery have been conventional neoadjuvant approaches. Recent trials favor LCRT due to improved local control. However, distant tumor recurrence remains a concern, prompting the exploration of total neoadjuvant therapy (TNT) as a comprehensive treatment strategy. Immune checkpoint inhibitors (ICIs) show promise, particularly in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, potentially revolutionizing neoadjuvant regimens. Nonoperative management (NOM) represents a viable alternative post-neoadjuvant therapy for selected patients achieving complete clinical response (cCR). Additionally, monitoring minimal residual disease (MRD) using circulating tumor DNA (ctDNA) emerges as a non-invasive method for the assessment of treatment response. This review synthesizes current evidence on TNT, ICIs, NOM, and ctDNA, elucidating their implications for rectal cancer management and highlighting avenues for future research and clinical application. Full article
Show Figures

Figure 1

15 pages, 1209 KiB  
Review
Early Rectal Cancer and Local Excision: A Narrative Review
by Cecilia Binda, Matteo Secco, Luigi Tuccillo, Chiara Coluccio, Elisa Liverani, Carlo Felix Maria Jung, Carlo Fabbri and Giulia Gibiino
J. Clin. Med. 2024, 13(8), 2292; https://doi.org/10.3390/jcm13082292 - 16 Apr 2024
Viewed by 714
Abstract
A rise in the incidence of early rectal cancer consequent to bowel-screening programs around the world and an increase in the incidence in young adults has led to a growing interest in organ-sparing treatment options. The rectum, being the most distal portion of [...] Read more.
A rise in the incidence of early rectal cancer consequent to bowel-screening programs around the world and an increase in the incidence in young adults has led to a growing interest in organ-sparing treatment options. The rectum, being the most distal portion of the large intestine, is a fertile ground for local excision techniques performed with endoscopic or surgical techniques. Moreover, the advancement in endoscopic optical evaluation and the better definition of imaging techniques allow for a more precise local staging of early rectal cancer. Although the local treatment of early rectal cancer seems promising, in clinical practice, a significant number of patients who could benefit from local excision techniques undergo total mesorectal excision (TME) as the first approach. All relevant prospective clinical trials were identified through a computer-assisted search of the PubMed, EMBASE, and Medline databases until January 2024. This review is dedicated to endoscopic and surgical local excision in the treatment of early rectal cancer and highlights its possible role in current and future clinical practice, taking into account surgical completion techniques and chemoradiotherapy. Full article
Show Figures

Figure 1

Back to TopTop